

CONFIDENTIAL

**Comprehensive COLARIS AP[®]
MYH Analysis Result**

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD Comprehensive Medical Center 1100 Grand Ave Away, GA 12345	Specimen: Blood Draw date: Aug 01, 2010 Accession date: Aug 02, 2010 Report Date: Aug 12, 2010	Name: Doe, Jane Date of Birth: April 1, 1492 Patient ID: 000000 Gender: Female Accession #: 00000000-BLD Requisition #: 000000

Test Results and Interpretation

ONE MYH MUTATION DETECTED, COLORECTAL POLYPOSIS AND CANCER RISK UNKNOWN

<u>Test Performed:</u> MYH sequencing	<u>Result:</u> IVS10+3A>C, 1 copy	<u>Interpretation:</u> Clinical significance undetermined
--	--------------------------------------	--

Analysis consists of sequencing of all exons and immediately adjacent intronic regions of the MYH gene. The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

This analysis detected a single copy of the MYH mutation, IVS10+3A>C. Full sequence analysis of MYH did not detect a second mutation. It is currently unknown whether individuals who carry a single MYH mutation are at some measure of increased risk for colorectal polyposis and cancer. Current data are limited but suggest that any increase in risk, if present, is likely to be small (N Engl J Med 2003;348:791-799; Lancet 2003;362:39-41; J Natl Cancer Inst 2004;96:1631-1634). Medical management should be determined by clinical findings and personal and family history of colorectal polyposis and/or cancer. Baseline colonoscopy has been suggested in these individuals and if negative, repeat colonoscopy at regular intervals (Gastroenterology 2004; 127:9-16).

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.